June, 2026
What makes CGT trial execution so complex?
It starts with trial design.
Where will patients be recruited? Where will material be collected? Where will manufacturing take place? Which approvals are needed before the therapy can move? How will the final product be returned within its viable treatment window?
Each decision shapes the clinical trial supply chain before the first shipment takes place.
That’s what makes CGT trial execution so complex. It’s not one process. It’s a connected pathway where clinical operations, manufacturing, regulatory approval, cold chain distribution, and patient care all need to move together.
The patient pathway drives the supply chain
In many clinical trials, products move through a planned distribution model.
In CGT, the patient often sets the process in motion.
A patient is identified and enrolled. Biological material may then be collected, prepared, and transported to a specialist manufacturing site. Once processed into a personalized therapy, the product must be released, returned, and administered within a defined window.
This changes the role of clinical trial logistics.
The clinical trial supply chain is no longer built around stock movement alone. It must respond to an individual patient pathway, while maintaining chain of custody, product integrity, and clinical trial compliance throughout.
For cell and gene therapy companies, this creates a very different planning challenge.
The pathway has to work in the real world
On paper, a CGT pathway can look straightforward:
Patient → collection → manufacturing → approval → return → administration
In practice, each stage introduces additional risk.
A collection appointment may need to align with courier availability. Manufacturing may take place in another country. Qualified Person (QP) release for clinical trial products may need to happen before the therapy can be supplied. Return transport may depend on flight availability, customs clearance, site readiness, and cold chain conditions. In some cases, a delay of only a few hours can disrupt the entire treatment window.
The pathway only works if every stage is planned around the next one.
That’s why CGT supply chain management needs to be built around real-world constraints, not ideal conditions.
Time becomes a clinical constraint
In CGT trials, time is not simply an operational measure.
It can affect whether a therapy remains viable, whether a patient can receive treatment, and whether a clinical trial can stay on track.
This is especially important when therapies are patient-specific and treatment windows are narrow. Once a product is ready for release, the clock is already ticking.
Clinical trial logistics management must therefore account for more than transport time. It must consider site readiness, approval steps, customs processes, contingency routing, and communication between stakeholders.
In this environment, a delay is rarely isolated. It can move through the pathway and affect everything that follows.
Temperature control must be designed into the journey
Many CGT products require highly controlled conditions, including ultra-low temperature storage or specialized cryogenic storage.
This makes temperature control a design consideration, not a late-stage logistics decision.
Clinical trial cold chain packaging, temperature controlled pharmaceutical storage, cold chain distribution, and cold chain pharmaceutical distribution all need to be planned around the therapy, the route, and the treatment window.
The same applies to labeling and packaging.
Clinical trial labeling, labeling compliance, secondary packaging, and all temperature package labeling must support safe, compliant movement across the pathway. If labeling regulations are not met, or if packaging is not suitable for the required conditions, the product may be delayed before it ever reaches the patient.
Compliance has to move at the speed of the pathway
CGT trials do not reduce the need for regulatory control.
They increase the need for regulatory coordination.
Clinical trial regulatory management, supply chain regulatory compliance, pharmaceutical compliance, QP batch release, and QP release of Investigational Medicinal Product (IMP) all need to align with tight delivery timeframes.
This is where pressure builds.
The therapy cannot simply move because it’s ready. It must be ready, compliant, released, documented, and deliverable.
For global trials, that complexity increases further. Different countries may have different requirements for clinical trial compliance, pharmaceutical regulation, labeling regulations, import processes, and site-level procedures.
The result is a pathway where compliance cannot sit separately from operations. It has to be built into the execution model from the beginning.
Coordination is the real test
CGT trial execution depends on many organizations acting as one connected system.
That may include:
-
The trial sponsor
-
Clinical sites
-
Collection teams
-
Manufacturing partners
-
Logistics providers
-
Regulatory teams
-
Quality teams
-
Packaging and labeling teams
-
Pharmacists and treating clinicians
No single function controls the full pathway.
This is why cell and gene therapy logistics requires more than transport capability. It requires visibility, communication, escalation planning, and shared accountability across the clinical supply chain.
When coordination works, the process can appear seamless.
When it doesn’t, complexity becomes visible very quickly.
Why execution planning needs to start earlier
The biggest risks in CGT trial execution often appear during delivery, but they are usually created much earlier.
If clinical trial supply chain management is considered too late, teams may discover that the trial design is difficult to execute in certain markets, that manufacturing and return timelines are too tight, or that regulatory steps are not aligned with the treatment window.
Earlier planning helps teams understand:
-
Whether the pathway is operationally viable
-
Which markets create additional regulatory complexity
-
Where cold chain storage or cryostorage for cell therapies may be needed
-
How IMP distribution should be managed
-
What contingency plans are required if a shipment, approval, or site process is delayed
This is where specialist cell and gene services can add value — not by replacing internal teams, but by helping design execution around the realities of delivery.
What CGT complexity really means
CGT trial execution is complex because the process is personal, time-critical, regulated, temperature-sensitive, and globally connected.
But the real challenge is not any one of those factors.
It’s the way they interact.
A delay in approval can affect logistics. A logistics issue can affect temperature control. A temperature deviation can affect product viability. A site readiness issue can affect administration. A patient-specific pathway can leave little room to recover.
That’s why CGT execution has to be planned as an integrated system.
For clinical development leaders, the question is no longer simply whether the science is ready.
It’s whether the pathway is ready to deliver it.
